CAPTCHA as a Visual Performance Metric in Active Macular Disease
Table 1
Baseline demographics and clinical characteristics for active disease (either intraretinal fluid or subretinal fluid) and pseudophakic control patients.
Active disease
Control
value
Mean ± Std. dev.
Mean ± Std. dev.
Age
69.2 ± 15.0
69.7 ± 8.0
0.55
Gender
Female
21 (47.7%)
23 (52.3%)
0.82
Male
12 (53.3%)
14 (46.7%)
Race
White
25 (75.7%)
30 (81.1%)
0.21
Black
2 (6.1%)
2 (5.4%)
Asian
0 (0%)
3 (8.1%)
Hispanic
6 (18.1%)
2 (5.4%)
Visual acuity group
1 (20/20)
6 (18.2%)
10 (27.0%)
0.83
2 (20/25)
7 (21.2%)
10 (27.0%)
3 (20/30)
6 (18.2%)
6 (16.2%)
4 (20/40)
9 (27.2%)
3 (8.1%)
5 (20/50)
5 (15.2%)
8 (21.6%)
BCVA near logMAR
0.19 ± 0.14
0.17 ± 0.15
0.65
Disease
DME
14 (42.4%)
—
—
AMD
19 (57.6%)
—
—
No statistically significant difference was found between active disease and control cohort for any baseline characteristics. BCVA: best-corrected visual acuity, DME: diabetic macular edema, and AMD: age-related macular degeneration.
